Practices
Industries
Value-Added Services
Developing innovative pricing structures and alternative fee agreement models that deliver additional value for our clients.
Advancing professional knowledge and offering credits for attorneys, staff and other professionals.
Helping clients respond correctly when a crisis occurs.
Providing our clients with legal, strategic, and practical advice to make transformational changes in their organizations.
Leveraging law and technology to deliver sound solutions.
Delivering seamless service through partnerships across the globe.
Leveraging leading-edge technology to guide change and create seamless, collaborative experiences for clients and attorneys.
Industry-leading conferences focused on affordable housing, tax credits, and more.
Providing actionable information to support strategic decision-making.
Teaming with clients to advance sustainable projects, mitigate the effects of climate change, and protect our planet.
Offering a range of investment management and fiduciary services.
Bringing together companies and investors for tomorrow’s new deals.
Offering fresh insights on cases that are delayed, over budget, or off-target from the desired resolution.
Courtroom-ready lawyers who can resolve disputes early on clients’ terms or prevail at trial before a judge or jury.
Creating positive impact in our communities through increasing equity, access, and opportunity.
Partner / Leader, False Claims Act Team
I'm a 2023 Nixon Peabody Pro Bono Champion.Read more about our Pro Bono program
Adam Tarosky is a member of the Government Investigations & White-Collar Defense practice group and leads the False Claims Act Team. He came to Nixon Peabody from one of the most powerful offices in the Department of Justice. The Civil Division’s Fraud Section, the clearinghouse for all False Claims Act activity in the country, annually coordinates the recovery of billions of dollars from healthcare providers, defense contractors, and federal program beneficiaries. Adam uses the knowledge and insight that he obtained as a trial attorney with the Fraud Section to counsel clients through FCA investigations and qui tam and government-initiated litigation.
Adam also provides regulatory compliance counsel; represents clients facing administrative sanctions like debarment, exclusion, and suspension; guides healthcare providers through medical record reviews and program integrity audits; and maintains an extensive general commercial litigation practice.
I represent clients in heavily regulated industries, including healthcare, defense contracting, and financial services facing government investigation and litigation under the False Claims Act, Anti-Kickback Statute, Provider Self-Referral Law, Civil Monetary Penalties Law, Food Drug and Cosmetics Act, and Federal Acquisition Regulation.
I advise on compliance with the FCA and statutes and regulations that commonly underlie FCA actions, manage internal investigations, direct responses to civil investigative demands and subpoenas, work to convince the government to decline to prosecute FCA allegations or resolve them on favorable terms, and litigate FCA claims by whistleblowers or the United States through motions, discovery, and trial. Throughout such representations, I identify and strategically guide clients through potentially parallel administrative and criminal liability.
In addition to my FCA compliance and defense practice, I regularly advocate before government agencies, including the Department of Health and Human Services Office of Inspector General, the Centers for Medicare and Medicaid Services, and the Department of Defense, to protect providers and contractors from debarment, exclusion, suspension, civil monetary penalties, and unduly burdensome corporate integrity agreements and monitorships. I also help clients respond effectively to pre- and post-payment reviews by Medicare Administrative Contractors and Recovery Audit Contractors, and to program integrity audits by Unified Program Integrity Contractors.
Before joining Nixon Peabody, I served as a trial attorney in the Civil Division’s Fraud Section, the office that oversees nearly every FCA investigation, qui tam proceeding, litigation, and trial in the country. There, I led high-profile enforcement actions against, among others, the country’s highest paid Medicare cardiologist, the estate of a bank executive charged with misappropriating Troubled Asset Relief Program funds, and the former chief financial officer of a global professional services firm that overbilled the United States for reconstruction work in Iraq and Afghanistan. I investigated and resolved other matters short of litigation, including through settlements with a major purveyor of residential mortgage-backed securities and a nationwide mail-order pharmacy. Together, these efforts resulted in the recovery of over $100 million.
During my time at the DOJ, I also served as a Special Assistant United States Attorney in the Major Crimes Section of the United States Attorney’s Office for the District of Columbia, prosecuting criminal actions involving trespass, assault, theft, drugs, weapons, and firearm-related offenses.
Prior to my government service, I was a senior associate at a renowned trial and white-collar defense firm in Washington, DC, and before that, I clerked for Judge Thomas M. Hardiman of the United States Court of Appeals for the Third Circuit.
Throughout my career, I have tried or assisted in trying dozens of civil and criminal cases, including a seminal consumer fraud matter involving average wholesale pharmaceutical pricing. I took numerous other cases to the brink of trial, including FCA cases involving allegedly unnecessary hospital admissions and fraud on a state Medicaid agency’s sole community provider program.
The False Claims Act will continue to be a major source of revenue for the government, and a major source of potentially catastrophic financial, operational, and reputational risk to individuals and entities that do business with it.
Since 1986, FCA recoveries have exceeded $72 billion. At the same time, qui tam actions have continued to proliferate. Over 600 qui tam actions have been filed each year since 2011 and, last year, the government brought a record 296 FCA actions on its own.
Although the government has increasingly exercised its statutory prerogative to dismiss qui tam actions, tenuous allegations continue to be litigated long after the government declines, forcing defendants to zealously defend themselves or risk treble damages, mandatory civil penalties, and likely administrative sanctions.
In parallel with increasing federal enforcement of the FCA, 31 states now have FCA-like statutes of their own, and interstate coordination of investigation and enforcement efforts, including through sophisticated data analysis and information sharing, is becoming more efficient and robust. State Attorneys General and Medicaid Fraud Control Units are likely to take increasingly significant roles in fraud, waste, and abuse enforcement in the coming years.
All of this means that those who do business with the United States and state governments need experienced counsel who understands the priorities, procedures, and at times peculiarities of the government, and who maintains close relationships with federal prosecutors, civil enforcement attorneys, agency counsel, and federal program personnel across the country.
I am one of a small group of defense attorneys with an insider’s understanding of the DOJ and the Fraud Section who has also amassed significant criminal, regulatory, and private sector experience. My unique knowledge and insight generate exceptional results for clients.
Government Investigations & White-Collar Defense practice leader Rob Fisher of Boston, partner Adam Tarosky of Washington, DC, and associate Jarrad Kirsh of Boston and Washington, DC Complex Disputes counsel Brian Hill contributed this article, discussing a case pending before the US Supreme Court that will determine whether requests to the E-Rate program count as claims under the False Claims Act.
Washington, DC Government Investigations & White-Collar Defense partner Adam Tarosky joins this program to discuss NP’s sponsorship and participation in the Leukemia and Lymphoma Society’s (LLS) Light the Night Walk and its direct connection with the firm’s social impact initiatives. Adam is a member of the LLS executive committee.
This article covers how new Justice Department allegations that Regeneron Pharmaceuticals Inc. artificially inflated Medicare reimbursement rates on its Eylea drug could trigger similar complaints at other pharmaceutical manufacturers. Washington, DC Government Investigations & White-Collar Defense partner Adam Tarosky, leader of the firm’s False Claims Act team, discusses whether this may be just the tip of the iceberg of a coming wave of average sales price litigation.
This article covers the US Court of Appeals for the First Circuit affirming a district court’s dismissal of a False Claims Act case against DePuy Orthopaedics, DePuy Inc., and Johnson & Johnson related to hip replacement devices. The story mentions NP for representing the defendants in the case, with the team including Washington, DC Government Investigations & White-Collar Defense partner and False Claims Act team leader Adam Tarosky, and Boston GIWC partners Mark Seltzer and Hannah Bornstein, GIWC deputy practice leader.
This article, which covers the dismissal of a lawsuit against medical device maker Bracco USA Inc. and several healthcare providers over an alleged scheme involving free medical equipment, mentions NP for representing one of the providers in the case (NYU Langone Health System Inc.). The NP team includes Long Island Healthcare partners Lindsay Maleson and Rebecca Simone, and Government Investigations & White-Collar Defense partner Adam Tarosky and associate Bobby McManigal, both of the Washington, DC office.
NP’s Christopher Hotaling, Adam Tarosky, Scott O’Connell and Colin Missett authored this article detailing key considerations for businesses to consider, given that funds under the CARES Act come with associated responsibilities for recipients, creating potential criminal and civil liability if not properly handled.
Washington, D.C. Government Investigations and White-Collar Defense partner Adam Tarosky discussed the possible compliance issues that may arise for businesses accepting government funds as part of the CARES Act.
This article highlights the arrival of Washington DC Government Investigations and White Collar Defense partner John Sandweg, a former acting director of Immigration and Customs Enforcement.
John comes to NP after leading his own boutique firm, Frontier Solutions. He joins NP along with five team members: counsel Rachel Winkler, associate Catherine Ingram Hunstad, legal assistant Tracey Ford, and investigative directors Jerry Robinette and Miguel Unzueta. John and his five colleagues will spearhead our firm’s new Cross-Border Risks team.
This article also quotes Washington DC Government Investigations and White Collar Defense partner Adam Tarosky on current trends in False Claims Act prosecutions.
District of Columbia
Pennsylvania
U.S. Court of Appeals, First Circuit
U.S. Court of Appeals, Third Circuit
U.S. Court of Appeals, Ninth Circuit
U.S. Court of Appeals, District of Columbia Circuit
U.S. District Court, District of Columbia
U.S. District Court, Western District of Pennsylvania
U.S. District Court, Eastern District of Pennsylvania
U.S. District Court, Middle District of Pennsylvania
Duke University School of Law, J.D., magna cum laude
Pennsylvania State University Schreyer Honors College, B.A.
Press Release
Stay informed of the latest legal news, alerts, and business trends.Subscribe